Payment overview · 2025
General Payments
$459.36
33 reported records · 9 companies
Healthcare provider profile · identity verified
Jennifer Jacobs, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DOVER, AR · NPI 1134622806
Verified facts
What the public records show
CMS Open Payments records show Jennifer Jacobs, APRN received $459.36 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.28 | 30.3% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $126.92 | 27.6% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.10 | 13.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.68 | 6.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.30 | 6.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.01 | 5.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.21 | 3.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $13.61 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.36 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $139.28 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $126.92 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $63.10 | 4 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 162 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 40 |
| Lisinopril | Lisinopril | 121 | 33 |
| Simvastatin | Simvastatin | 118 | 35 |
| Metformin Hcl | Metformin Hcl | 106 | 26 |
| Gabapentin | Gabapentin | 101 | 30 |
| Meloxicam | Meloxicam | 98 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 25 |
| Prednisone | Prednisone | 76 | 60 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 24 |
| Losartan Potassium | Losartan Potassium | 61 | 23 |
| Potassium Chloride | Potassium Chloride | 61 | 22 |
| Atenolol | Atenolol | 60 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 16 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 31 |
| Furosemide | Furosemide | 52 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | 12 |
| Sucralfate | Sucralfate | 36 | 20 |
| Famotidine | Famotidine | 35 | suppressed |
| Glipizide | Glipizide | 35 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 29 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 15 |
| Ozempic | Semaglutide | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 11 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 18 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 19 | 17 |
| Naproxen | Naproxen | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 11 |
| Belsomra | Suvorexant | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.36 · 33 records | ABBVIE INC. | AIRSUPRA, Auvelity, Bimzelx, CAPLYTA, Cologuard Collection Kit, GVOKE HYPOPEN, NUZYRA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, XHANCE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error